APOA-I MILANO
ApoA-I Milano is a company that was acquired by The Medicines Company in 2009.
Similar Organizations
Level9 Media
Level9 Media is a company that was acquired by b5media in 2007.
MHR-Viandes.com
MHR-Viandes.com is a company that was acquired by GET Holding NV in 2007.
Toytown Germany
Toytown Germany is a company that was acquired by The Local in 2008.
More informations about "ApoA-I Milano"
A consensus model of human apolipoprotein A-I in its …
Nov 13, 2017 Indeed, the natural mutations G26R in apoA-I IOWA 39 and R173C in apoA-I MILANO 40 both result in substantial decreases in free …See details»
Apolipoprotein AI - Wikipedia
As a major component of the high-density lipoprotein complex (protective "fat removal" particles), Apo-AI helps to clear fats, including cholesterol, from white blood cells within artery walls, making the white blood cells (WBCs) less likely to become fat overloaded, transform into foam cells, die and contribute to progressive atheroma. Five of nine men found to carry a mutation (E164X) who were at least 35 years of age had developed premature coronary artery disease. One of four mu…See details»
Structural and functional consequences of the Milano mutation …
The introduction of a cysteine residue allows apoA-I to form apoA-I Milano (apoA-I M) homodimers or heterodimers with apoA-II . The apoA-I M mutation is located in the N-terminal …See details»
Secondary Structure Changes in ApoA-I Milano (R173C) Are Not ...
Described carriers of the Milano variant of apoA-I are heterozygotes and have very low plasma levels of apoA-I and HDL cholesterol as well as normal or moderately elevated plasma …See details»
Apolipoproteins in vascular biology and atherosclerotic disease
Oct 8, 2021 ApoA-I Milano is a naturally occurring genetic variant with an arginine-to-cysteine substitution at position 173. This genetic variant attracted attention because carriers had lower …See details»
Secondary Structure Changes in ApoA-I Milano (R173C) Are Not
Apr 22, 2014 Described carriers of the Milano variant of apoA-I are heterozygotes and have very low plasma levels of apoA-I and HDL cholesterol as well as normal or moderately elevated …See details»
Cardiovascular Status of Carriers of the Apolipoprotein A-I
Apr 17, 2001 The apolipoprotein A-I Milano (apoA-I M) mutation was described in 1980 in a family originating from Limone sul Garda in northern Italy. 1 This apoA-I variant shows a single …See details»
Apolipoprotein A-I: structure–function relationships
Jun 1, 2000 ApoA-I is known to self-associate, a process which may stabilize the lipid-free protein. However, at low concentrations (below 0.1 mg/ml) (19), or in the presence of …See details»
Apolipoprotein A-I (ApoA-I), Immunity, Inflammation and Cancer
The first of these approaches can be accomplished by intravenous administration of autologous delipidated HDL, purified native ApoA-I, or recombinant ApoA-I Milano protein, a mutated …See details»
Effects of the Iowa and Milano Mutations on Apolipoprotein A-I ...
Nov 6, 2012 The Iowa point mutation in apolipoprotein A-I (G26R; apoA-I Iowa) leads to a systemic amyloidosis condition and the Milano mutation (R173C; apoA-I Mil) is associated with …See details»
Wild-Type ApoA-I and the Milano Variant Have Similar …
Jul 5, 2007 Patients presenting with the Milano mutation (R173C) of the apolipoprotein (apo) A-I, have significantly lower plasma HDL levels and paradoxically do not develop premature atherosclerosis. 1,2 The mechanism …See details»
Gene transfer of wild-type apoA-I and apoA-I Milano reduce ...
May 2, 2007 The human ApoA-I-Milano gene was cloned via site directed mutagenesis of the wtApoA-I plasmid by PCR. Correct cloning was confirmed by sequencing and restriction digests. To produce AAV vectors encapsidated in an AAV8 capsid (AAV2.8), a pseudotyping strategy was performed as reported [18,19]. Vectors were purified using a standard cesium ...See details»
ApoA-II Versus ApoA-I | Arteriosclerosis, Thrombosis, and Vascular …
Dec 1, 2001 ApoA-I Milano variant increases triglycerides in humans and transgenic mice: Increased because increased production and decreased clearance of VLDL: No effect: Plasma …See details»
Apo-AI (Apo-A1) Milano - GPnotebook
The decrease in apoA-I levels among individuals with these structural mutations is the result of rapid catabolism of apoA-I (1) apoA-I Milano (2) results in an average 40% decrease in apoA-I …See details»
Apolipoprotein A-I: structure–function relationships
Feb 3, 2000 ApoA-I Milano (Arg 173 →Cys), which has been extensively studied also appears to be associated with size restricted HDL lipoproteins (smaller HDL and reduced number of HDL …See details»
Apolipoprotein A-I (Milano): current perspectives - PubMed
Furthermore, recombinant apolipoprotein A-I(Milano) has displayed remarkable atheroprotective activities and the possibility of directly reducing the burden of atherosclerosis in experimental …See details»
The Long Saga of Apo-A1 Milano | Science - AAAS
Nov 16, 2016 It's been six years since I titled a post "Remember Apo-A1 Milano?" If you go back even further, I wrote about the topic on this blog back in 2003 (!); scroll down to the November …See details»
ApoA-I Infusion Therapies Following Acute Coronary Syndrome: …
May 7, 2022 MDCO-216 contains recombinant ApoA-I Milano, CER-001 contains recombinant wild-type human ApoA-I, and CSL111/CSL112 contains native ApoA-I isolated from human …See details»
ApoA-I Milano stimulates lipolysis in adipose cells independently …
ApoA-I Milano treatment induces rapid weight loss and increased lipolysis. C57bl6/J mice received one intraperitoneal injection/day of ApoA-I Milano (20 mg/kg), WT (20 mg/kg), or saline (NaCl), during 6 days (n = 6–11 animals/group). Body weight was monitored daily during the treatment and 24 h after the last injection (day 0 first injection ...See details»
ApoA-I Milano/phospholipid complexes emerging pharmacological …
Recently, much attention has focused on a naturally occurring variant of apoA-I, apoA-I(Milano) (apoA-IM) characterized by a cysteine for arginine substitution that is associated with low rates of vascular disease and significant longevity in its carriers, despite markedly reduced HDL and elevated triglyceride levels.See details»